Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)

Summary

The main objective of the study is to see if using anti-inflammatory to patients with airway disease chronic obstructive pulmonary disease (COPD) phenotype will be more effective than using these treatments in patients with loss of lung tissue. Symbicort plus ipratropium/albuterol will be used for 12 weeks in an open-label study in subjects with airway predominant COPD.

Timeline

Start

2012-04

Primary completion

2015-09

Completion

2016-01

Drugs

Indications